91 related articles for article (PubMed ID: 8643882)
21. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
22. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT).
Frishman WH; Hainer JW; Sugg J;
Am J Hypertens; 2006 Apr; 19(4):388-95. PubMed ID: 16580575
[TBL] [Abstract][Full Text] [Related]
23. A comparison of the statistical power of different methods for the analysis of cluster randomization trials with binary outcomes.
Austin PC
Stat Med; 2007 Aug; 26(19):3550-65. PubMed ID: 17238238
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
Wald DS; Law M; Morris JK; Bestwick JP; Wald NJ
Am J Med; 2009 Mar; 122(3):290-300. PubMed ID: 19272490
[TBL] [Abstract][Full Text] [Related]
25. Targeting systolic blood pressure: the key to controlling combined systolic/diastolic hypertension.
Waeber B; Mourad JJ
Am J Hypertens; 2006 Sep; 19(9):985-6. PubMed ID: 16942945
[No Abstract] [Full Text] [Related]
26. [Amlodipine is the better partner].
Einecke D
MMW Fortschr Med; 2008 Apr; 150(16):13-4. PubMed ID: 18557108
[No Abstract] [Full Text] [Related]
27. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
28. A practical limit to trials needed in one-person randomized controlled experiments.
Alemi R; Alemi F
Qual Manag Health Care; 2007; 16(2):130-4. PubMed ID: 17426611
[TBL] [Abstract][Full Text] [Related]
29. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
30. Predictors of failure to initiate randomized treatment in a large trial of antihypertensive drug therapy in the aged.
Nelson MR; Ryan P; Willson K; Reid CM; Beilin LJ; Jennings GL; Johnston CI; Macdonald GJ; Marley JE; McNeil JJ; Morgan TO; West MJ; Wing LM
Am J Hypertens; 2005 Jun; 18(6):885-8. PubMed ID: 15925752
[TBL] [Abstract][Full Text] [Related]
31. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
32. Hypertension: treating the patient as well as the blood pressure.
Jackson G
Int J Clin Pract; 2003 Jun; 57(5):357. PubMed ID: 12846335
[No Abstract] [Full Text] [Related]
33. Power comparison of robust approximate and non-parametric tests for the analysis of cross-over trials.
Correa JA; Bellavance F
Stat Med; 2001 Apr; 20(8):1185-96. PubMed ID: 11304735
[TBL] [Abstract][Full Text] [Related]
34. Application of response surface methodology and factorial designs to clinical trials for drug combination development.
Stewart WH
J Biopharm Stat; 1996 Jul; 6(3):219-30. PubMed ID: 8854227
[TBL] [Abstract][Full Text] [Related]
35. Efficacy evaluation for monotherapies in two-by-two factorial trials.
Hung HM; Chi GY; O'Neill RT
Biometrics; 1995 Dec; 51(4):1483-93. PubMed ID: 8589235
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the interaction between the therapy and the treatment in clinical trials by the propensity score weighting method.
Fujii Y; Henmi M; Fujita T
Stat Med; 2012 Feb; 31(3):235-52. PubMed ID: 22253134
[TBL] [Abstract][Full Text] [Related]
37. Performance and sample size requirements of Bayesian methods for binary outcomes in fixed-dose combination drug studies.
Holt MM; Stamey JD; Seaman JW; Young DM
J Biopharm Stat; 2009; 19(1):120-32. PubMed ID: 19127471
[TBL] [Abstract][Full Text] [Related]
38. The use of baseline covariates in crossover studies.
Kenward MG; Roger JH
Biostatistics; 2010 Jan; 11(1):1-17. PubMed ID: 19915170
[TBL] [Abstract][Full Text] [Related]
39. Estimating dose-response effects in psychological treatment trials: the role of instrumental variables.
Maracy M; Dunn G
Stat Methods Med Res; 2011 Jun; 20(3):191-215. PubMed ID: 19036909
[TBL] [Abstract][Full Text] [Related]
40. Cumulative statistical power for hierarchical comparisons to evaluate two combination drug doses.
Matsukura T; Koch GG
J Biopharm Stat; 2008; 18(4):750-72. PubMed ID: 18607806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
